跳至主要内容
临床试验/EUCTR2016-000502-11-GB
EUCTR2016-000502-11-GB进行中(未招募)1 期

Study of the Optimum Duration of Acoustic Pulse Thrombolysis (APT) Procedure in the Treatment of Acute Submassive Pulmonary Embolism (OPTALYSE PE). - EKOS and r-tPA thrombolysis in Pulmonary Embolism (OPTALYSE STUDY)

EKOS Corporation0 个研究点目标入组 150 人开始时间: 2016年10月17日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Male or female = 18 years of age and = 75 years of age
  • 2.Computed tomography angiography (CTA) evidence of proximal pulmonary embolism (PE) (filling defect in at least one main or lobar pulmonary artery)
  • 3.PE symptom duration =14 days
  • 4.Submassive PE: RV/LV diameter = 0.9 from CTA and haemodynamically stable
  • 5.Treatment must be started within 48 hours of diagnosis of PE by CTA
  • 6.Signed Informed consent obtained from subject or Legally Authorized Representative
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • 1.Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year
  • 2.Recent (within one month) active bleeding from a major organ
  • 3.Major surgery within seven days of screening for study enrollment
  • 4.Clinician deems the subject high-risk for catastrophic bleeding
  • 5.History of heparin-induced thrombocytopaenia (HIT)
  • 6.Catheter-based pharmacomechanical treatment for PE within 3 days of study enrollment
  • 7.Systolic blood pressure (SBP) less than 90 mm Hg and/or use of vasopressors
  • 8.Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR)
  • 9.Evidence of irreversible neurological compromise
  • 10.Life expectancy < one year
  • 11.Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to APT procedure
  • 12.Out-of-Range haematological parameter laboratory values: Haematocrit < 30%, Platelets < 100 thousand/µL, INR > 3,
  • 13.Creatinine outside the normal range for the treating institution
  • 14.Subject is pregnant (positive pregnancy test; women of childbearing capacity must be tested) or breast feeding
  • 15.Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: subjects with non-melanoma primary skin cancers are eligible to participate in the study
  • 16.Known allergy, hypersensitivity, or thrombocytopaenia from heparin, r-tPA, or iodinated contrast except for mild-moderate contrast allergies for which steroid pre-medication can be used

研究者

发起方
EKOS Corporation

相似试验